Gilman Pergament LLP

Firm Profile

Firm Profile


Pergament & Cepeda LLP has a headquarters location in Morristown, NJ.

Edward D. Pergament held several positions as a synthetic chemist with generic and brand pharmaceutical companies and subsequently had been a legal executive in the pharmaceutical industry, including a position as Vice-President-Patents for Dr. Reddy's Laboratories, Ltd. Edward leads chemical/pharmaceutical practice group at Pergament & Cepeda LLP. As an attorney, Edward counsels clients with respect to patent strategy with concentration in the chemical and pharmaceutical arts, oversees patent procurement and manages patent portfolios, overseas due diligence and opinion matters, and litigates disputes in U.S. federal courts, with particular concentration in ANDA litigation. He has considerable experience in legal, business and technical issues related to pharmaceutical solids (API), generics, specialty formulations, platform technologies, small molecule NCEs and biologics, cosmetic products, fine chemicals, medical devices, and vapor deposition technologies. Edward has been involved in generic product selection for generic pharmaceutical companies, lifecycle management strategy for brand pharmaceuticals, creation of proprietary position for specialty products, and has had considerable exposure to global IP issues, and has hand-on understanding of business issues and their interface with intellectual property involved in a broad range of pharmaceutical, cosmetic and chemical products.

Milagros A. Cepeda heads up the firm’s chemical and pharmaceutical patent prosecution practice and is the managing partner of the firm. Milagros has broad patent experience, including roles in the pharmaceutical industry as in-house counsel for Bristol-Myers Squibb, Coulter Corporation, American Home Products Novartis Pharmaceuticals Corporation and Dr. Reddy’s Laboratories. As in-house counsel Milagros was responsible for patent preparation and prosecution, client counseling regarding the development and implementation of life cycle management strategies regarding key products, evaluation of intellectual property portfolios and drafting of agreements in association with licensing and acquisition of pharmaceutical products from third parties.